TDS Granted a Business Method Patent

TDS (Trial Dealmaking Support), DanteVision’s B2B SaaS solution for CROs, has been granted a business method (BM) patent.

Filed in October 2024, the patent was registered in June 2026 after about one year and seven months of examination (Korean Patent No. 10-2974297, “Apparatus and Method for Supporting Business Development of Contract Research Organization Services”). It formally recognizes the originality of TDS’s business structure and its clinical trial business development (BD) process management features.

Building on this, DanteVision will continue commercializing TDS and growing its customer base, while rolling out AI Chat–based quote drafting support and AI business insights.